Wedbush Issues Pessimistic Estimate for SWTX Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Stock analysts at Wedbush lowered their FY2027 earnings per share estimates for shares of SpringWorks Therapeutics in a report issued on Monday, January 13th. Wedbush analyst D. Nierengarten now expects that the company will earn $3.42 per share for the year, down from their previous forecast of $3.47. Wedbush currently has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.12) per share.

SWTX has been the subject of several other reports. HC Wainwright decreased their price objective on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. Guggenheim decreased their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Evercore ISI began coverage on shares of SpringWorks Therapeutics in a report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $70.00.

SpringWorks Therapeutics Stock Up 3.0 %

Shares of NASDAQ SWTX opened at $33.48 on Wednesday. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $53.92. The business’s 50 day moving average price is $37.97 and its 200 day moving average price is $36.40. The firm has a market cap of $2.49 billion, a P/E ratio of -8.63 and a beta of 0.82.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The business had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. During the same quarter in the previous year, the business earned ($1.27) EPS. The company’s quarterly revenue was up 4810.0% compared to the same quarter last year.

Institutional Trading of SpringWorks Therapeutics

Several institutional investors have recently bought and sold shares of the business. Profund Advisors LLC raised its stake in shares of SpringWorks Therapeutics by 1.3% during the 2nd quarter. Profund Advisors LLC now owns 29,048 shares of the company’s stock worth $1,094,000 after buying an additional 362 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in SpringWorks Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after acquiring an additional 474 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in SpringWorks Therapeutics by 1.9% during the third quarter. State of New Jersey Common Pension Fund D now owns 46,389 shares of the company’s stock worth $1,486,000 after acquiring an additional 871 shares during the period. E Fund Management Co. Ltd. lifted its holdings in SpringWorks Therapeutics by 11.6% during the second quarter. E Fund Management Co. Ltd. now owns 9,467 shares of the company’s stock valued at $357,000 after purchasing an additional 981 shares in the last quarter. Finally, Quarry LP grew its position in shares of SpringWorks Therapeutics by 20.0% in the third quarter. Quarry LP now owns 6,000 shares of the company’s stock valued at $192,000 after purchasing an additional 1,000 shares during the period.

Insider Buying and Selling

In related news, COO Badreddin Edris sold 20,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the transaction, the chief operating officer now owns 209,600 shares of the company’s stock, valued at approximately $8,796,912. This represents a 8.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.61% of the stock is currently owned by insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.